Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation
Open Access
- 23 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 20 (24), 4947-4977
- https://doi.org/10.1093/hmg/ddr432
Abstract
A functional genetic screen using loss-of-function and gain-of-function alleles was performed to identify modifiers of tau-induced neurotoxicity using the 2N/4R (full-length) isoform of wild-type human tau expressed in the fly retina. We previously reported eye pigment mutations, which create dysfunctional lysosomes, as potent modifiers; here, we report 37 additional genes identified from ∼1900 genes screened, including the kinases shaggy/GSK-3beta, par-1/MARK, CamKI and Mekk1. Tau acts synergistically with Mekk1 and p38 to down-regulate extracellular regulated kinase activity, with a corresponding decrease in AT8 immunoreactivity (pS202/T205), suggesting that tau can participate in signaling pathways to regulate its own kinases. Modifiers showed poor correlation with tau phosphorylation (using the AT8, 12E8 and AT270 epitopes); moreover, tested suppressors of wild-type tau were equally effective in suppressing toxicity of a phosphorylation-resistant S11A tau construct, demonstrating that changes in tau phosphorylation state are not required to suppress or enhance its toxicity. Genes related to autophagy, the cell cycle, RNA-associated proteins and chromatin-binding proteins constitute a large percentage of identified modifiers. Other functional categories identified include mitochondrial proteins, lipid trafficking, Golgi proteins, kinesins and dynein and the Hsp70/Hsp90-organizing protein (Hop). Network analysis uncovered several other genes highly associated with the functional modifiers, including genes related to the PI3K, Notch, BMP/TGF-β and Hedgehog pathways, and nuclear trafficking. Activity of GSK-3β is strongly upregulated due to TDP-43 expression, and reduced GSK-3β dosage is also a common suppressor of Aβ42 and TDP-43 toxicity. These findings suggest therapeutic targets other than mitigation of tau phosphorylation.This publication has 177 references indexed in Scilit:
- Alzheimer’s disease: diagnostics, prognostics and the road to preventionEPMA Journal, 2010
- Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 MutationsCell, 2010
- Abnormal mitochondrial dynamics and neurodegenerative diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Novel Hsp90 partners discovered using complementary proteomic approachesCell Stress and Chaperones, 2009
- Role of mitochondrial dysfunction in the pathogenesis of Huntington's diseaseBrain Research Bulletin, 2009
- FMR1: A gene with three facesBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- The Homotetrameric Kinesin-5 KLP61F Preferentially Crosslinks Microtubules into Antiparallel OrientationsCurrent Biology, 2008
- The amino terminus of tau inhibits kinesin‐dependent axonal transport: Implications for filament toxicityJournal of Neuroscience Research, 2008
- Phosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosisAnnals of Neurology, 2008
- The Lipid-Droplet Proteome Reveals that Droplets Are a Protein-Storage DepotCurrent Biology, 2006